Moderna to cut mRNA drug substance production at Lonza facility

Sep 20,2023

Contract drugmaker Lonza's facility in Visp, Switzerland, was dedicated to making vaccine ingredients and help boost the Moderna's deliveries to Europe, Canada and other nations outside the United States. Moderna expects to absorb the demand currently supported by Lonza at its internal manufacturing site at Norwood in Massachusetts for 2024-25.

Bengaluru: Moderna said on Tuesday it will cut production of drug substance for its COVID-19 vaccine Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand.

The U.S. company had said last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production.

Such a move will help Moderna adjust to the sharp fall in demand for vaccines as payers cut back orders for the shots, partly following the end of the public health emergency for the disease.

Contract drugmaker Lonza's facility in Visp, Switzerland, was dedicated to making vaccine ingredients and help boost the Moderna's deliveries to Europe, Canada and other nations outside the United States.

Moderna expects to absorb the demand currently supported by Lonza at its internal manufacturing site at Norwood in Massachusetts for 2024-25, the company said.

In 2025, Moderna expects additional capacity from its new mRNA manufacturing facilities in the UK, Canada and Australia when completed and also continues to maintain external drug substance capacity at Rovi in Spain.

Source: Economic Times